Ingalls & Snyder LLC Increases Stock Position in Kenvue Inc. (NYSE:KVUE)

Ingalls & Snyder LLC increased its position in shares of Kenvue Inc. (NYSE:KVUE) by 12.7% in the 3rd quarter, HoldingsChannel reports. The fund owned 771,342 shares of the company’s stock after acquiring an additional 86,825 shares during the period. Ingalls & Snyder LLC’s holdings in Kenvue were worth $17,841,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Leo Wealth LLC raised its stake in shares of Kenvue by 0.3% during the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after acquiring an additional 481 shares in the last quarter. Alerus Financial NA increased its stake in Kenvue by 0.3% during the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after purchasing an additional 491 shares in the last quarter. Massmutual Trust Co. FSB ADV increased its stake in Kenvue by 6.2% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock valued at $194,000 after purchasing an additional 492 shares in the last quarter. Wolff Wiese Magana LLC increased its stake in Kenvue by 0.7% during the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock valued at $1,781,000 after purchasing an additional 501 shares in the last quarter. Finally, Marathon Capital Management increased its stake in Kenvue by 0.3% during the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock valued at $2,722,000 after purchasing an additional 514 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 1.9 %

Shares of KVUE traded down $0.46 during trading on Tuesday, reaching $23.80. 1,208,224 shares of the company traded hands, compared to its average volume of 17,716,857. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The stock has a market cap of $45.63 billion, a PE ratio of 44.15, a price-to-earnings-growth ratio of 2.19 and a beta of 1.37. The stock has a 50-day simple moving average of $22.96 and a 200-day simple moving average of $21.02. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. During the same period last year, the business earned $0.31 earnings per share. The business’s revenue for the quarter was down .4% on a year-over-year basis. On average, analysts anticipate that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.45%. The ex-dividend date of this dividend was Wednesday, November 13th. Kenvue’s dividend payout ratio is presently 149.09%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. UBS Group increased their price target on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Bank of America increased their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Piper Sandler increased their price objective on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a report on Monday, September 23rd. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. increased their target price on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and an average target price of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.